Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to understand how adipose tissue (fat) and the gut microbiota (the bacteria in the gut) may influence brain function and cognition. It has been observed that changes in adipose tissue in animals such as mice and Drosophila (a type of insect) affect memory and other brain functions. Additionally, it is believed that the gut microbiota also plays an important role in cognition.
This study will explore how gene expression in adipose tissue, blood metabolites, and the gut microbiota are related to cognitive function, such as memory and thinking, in individuals with and without obesity. The investigation will also assess whether these factors can predict changes in the brain over time and how they influence sleep, physical activity, and blood sugar regulation.
Advanced technologies will be used to analyze samples of tissue, blood, and microbiota, with the goal of identifying new mechanisms through which obesity affects the brain. This research may contribute to the development of new diagnostic and therapeutic strategies for cognitive problems in individuals with obesity.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OBESITY | With 2 subgroups
| ||
| WITHOUT OBESITY | With 2 subgroups:
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Glycemic variability | Mean and standard deviation of glucose measures in mg/dL using a CGM 10 days. | 36 month |
| The percentage of time in glucose target range (glucose level 100mg/dl-125mg/dl) | 36 months | |
| The glycaemic risk measured with the low blood glucose index (LBGI) | Low blood glucose index (LBGI) is a parameter that quantifies the risk of glycaemic. | 36 months |
| The glycaemic variability measured with mean amplitude of glycaemic excursions (MAGE) | measured in mg/dl | 36 months |
| Minutes light sleep | Mean and standard deviation of minutes' light sleep measures by activity and sleep tracker device. | 36 months |
| Minutes deep sleep | Mean and standard deviation of minutes' deep sleep measures by activity and sleep tracker device. | 36 months |
| Minutes rapid eye movement (REM) | Mean and standard deviation of minutes REM measures by activity and sleep tracker device. | 36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Audioverbal memory | It will be measured by California Verbal Learning Test (CVLT). Minimum/maximum scale values (0-16), where 16 is a better audioverbal memory. | 36 months |
| Effect on gut microbiota |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
We will make use of the existing samples from the FATBANK cohort (a platform driven by CIBEROBN, managed by the IDIBGI Biobank, and part of the Spanish National Biobank Network). Participants in this cohort had previously signed informed consent to be contacted again. Therefore, the selected participants will be reappointed at the Endocrinology, Diabetes, and Nutrition Service (UDENTG) of the Dr. Josep Trueta Hospital.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| José Manuel Fernández-Real, M.D., Ph.D. | Contact | +34972940200 | jmfreal@idibgi.org |
| Name | Affiliation | Role |
|---|---|---|
| José Manuel Fernández-Real, M.D., Ph.D. | Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut d'Investigació Biomèdica de Girona (IDIBGI) | Recruiting | Girona | Girona | 17007 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35729225 | Background | Mayneris-Perxachs J, Arnoriaga-Rodriguez M, Garre-Olmo J, Puig J, Ramos R, Trelis M, Burokas A, Coll C, Zapata-Tona C, Pedraza S, Perez-Brocal V, Ramio L, Ricart W, Moya A, Jove M, Sol J, Portero-Otin M, Pamplona R, Maldonado R, Fernandez-Real JM. Presence of Blastocystis in gut microbiota is associated with cognitive traits and decreased executive function. ISME J. 2022 Sep;16(9):2181-2197. doi: 10.1038/s41396-022-01262-3. Epub 2022 Jun 21. | |
| 15630418 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
saliva, stool, blood and urine
Gut microbiota will be analysed by metagenomics and metabolomics.
| 36 months |
| Visual memory | It will be measured by Rey-Osterrieth Complex Figure. Minimum/maximum scale values (0-36), where 36 is a better visual memory. | 36 months |
| Depressive symptomatology | It will be measured by Patient Health Questionnaire-9 (PHQ-9). Minimum/maximum scale values (0-27), where ≥ 20 is severe depression. | 36 months |
| Impulsivity | It will be measured by Impulsive Behaviour Scale (UPPS-P). The test evaluates: Negative urgency (tendency to act rashly under extreme negative emotions), Lack of Premeditation (tendency to act without thinking), Lack of Perseverance (inability to remain focused on a task) and Sensation Seeking (tendency to seek out novel and thrilling experiences). All items are rated on a four point scale from 1 (strongly agree) to 4 (strongly disagree). | 36 months |
| Food Addiction | It will be measured by Yale Food Addiction Scale. It is a symptom score from 0-11, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, for substance dependence. Food addiction is diagnosed if ≥3 symptoms are reported. | 36 months |
| Behavioural inhibition | It will be measured by Sensitivity to Punishment and Sensitivity to Reward (SPSRQ). The scale of Sensitivity to Punishment is related to the behavioural inhibition system. It is made up of two subscales of 24 items each. For each subscale, the minimum score is 0 and the maximum score is 24, with higher scores indicating greater sensitivity to punishment or reward, respectively. | 36 months |
| Behavioural activation | It will be measured by Sensitivity to Punishment and Sensitivity to Reward (SPSRQ). The reward sensitivity scale is related to the behavioural activation system. The questionnaire consists of two subscales of 24 items each. Each subscale ranges from 0 (minimum) to 24 (maximum), where a higher score indicates greater sensitivity to reward or punishment, respectively. | 36 months |
| Visoconstructive function | It will be measured by Rey-Osterrieth Complex Figure. Minimum/maximum scale values (0-36), where 36 is a better visoconstructive function. | 36 months |
| Selective and alternating attention | It will be measured by Trail making test (Part A and B). | 36 months |
| Attention and working memory | It will be measured by the Digits subtest of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV). This subtest includes two parts: Digits Forward (measuring attention) and Digits Backward (measuring working memory). The total raw score ranges from 0 (minimum) to 30 (maximum), with higher scores indicating better attention and working memory capacity. | 36 months |
| Inhibition | It will be measured by Stroop Color-Word Test. | 36 months |
| Phonemic verbal fluency | It will be measured by PMR. | 36 months |
| Semantic verbal fluency | It will be measured by Animals test. The person must name as many animals as possible in 1 minute. The result is corrected by standard scores, according to age and level of education. | 36 months |
| Facial recognition | It will be measured by Picture of Facial Recognition Test (POFA). | 36 months |
| Emotion recognition | It will be measured by Benton Facial Recognition Test (BFRT). This test evaluates the recognition of the five basic emotions: happiness, sadness, surprise, disgust, and anger. | 36 months |
| Binge eating disorder | It will be measured by Binge Eating Scale (BES). The BES is one of the most widely used measures to assess binge eating disorder symptomatology. The BES score ranges from 0 to 46 and its cut-off point is greater than or equal to 27. Subjects with scores higher than 27 are more likely to suffer from binge eating disorder. | 36 months |
| Anxiety state | It will be measured by State-Trate Anxiety Inventory (STAI). This questionnaire evaluates state anxiety (S) and trait anxiety (R) through 20 items each, with a likert-type response scale of four alternatives. In the case of state anxiety, the scale goes from 0 (not at all) to 3 (a lot), while for trait anxiety it goes from 0 (almost never) to 3 (almost always). The higher the score, the greater the anxiety in both concepts. | 36 months |
| Effect on brain structure | Brain structure will be assessed using magnetic resonance imaging. | 36 months |
| Diffusion Tensor Imaging brain sequences | Diffusion Tensor Imaging was acquired at 1.5 T (Philips ingenia) using a single-shot spin echo sequence with echo-planar imaging (EPI), 50 contiguous slices, voxel size 2x2x2.5 mm3, TE/TR of 72/3581 ms/ms, a diffusion-weighting factor b = 800 s/mm2 and diffusion encoding along 32 directions. | 36 months |
| Brain iron accumulation | It will be assessed using magnetic resonance imaging using (R2*) | 36 months |
| Resting-state functional brain sequences | It will be assessed using magnetic resonance imaging (T2*-weighted echo-planar imaging). T2 * relaxation data will be acquired with a multi-echo gradient sequence with 10 equidistant echoes (first echo = 4.6ms; echo spacing = 4.6ms; repetition time = 1300ms). The value of T2 * will be calculated by adjusting the simple exponential terms for the signal decay of the respective echo time values. | 36 months |
| Insulin resistance | It will be measured by HOMA | 36 months |
| Markers of chronic inflammation (C-reactive protein, IL-6, adiponectin and soluble, tumour necrosis factor-α receptor fractions) | Enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR) | 36 months |
| Glycosylated haemoglobin (HbA1c) value | Glycosylated haemoglobin (HbA1c) in % or mmol/mol | 36 months |
| The percentage of time in hyperglycaemia (glucose level above 250 mg/dl) | 36 months |
| The percentage of time in hypoglycaemia (glucose level below 70mg/dl) | 36 months |
| The percentage of time in glucose range (glucose level below 100 mg/dl) | 36 months |
| The percentage of time in glucose range (glucose level between 126-139 mg/dl) | 36 months |
| The percentage of time in glucose range (glucose level between 140-199 mg/dl) | 36 months |
| The percentage of time in glucose range (glucose level above 200 mg/dl) | 36 months |
| Burned calories | Mean and standard deviation of burned calories measures by activity and sleep tracker device. | 36 months |
| Steps Mean and standard deviation of steps measures by activity and sleep tracker device. | The mean and standard deviation of steps refer to the average number of steps taken by a participant and how much those steps vary from the average, as measured by an activity and sleep tracker device. The mean is the average, while the standard deviation shows the variation or consistency in step count. | 36 months |
| Distance Mean and standard deviation of distance measures by activity and sleep tracker device. | 36 months |
| Minutes null activity | Mean and standard deviation of minutes' null activity measures by activity and sleep | 36 months |
| Minutes slight activity | Mean and standard deviation of minutes slight activity measures by activity and sleep | 36 months |
| Minutes mean activity | Mean and standard deviation of minutes mean activity measures by activity and sleep tracker device. | 36 months |
| Minutes high activity | Mean and standard deviation of minutes high activity measures by activity and sleep tracker device. | 36 months |
| Calories | Mean and standard deviation of calories measures by activity and sleep tracker device. | 36 months |
| Minutes asleep | Mean and standard deviation of minutes asleep measures by activity and sleep tracker. | 36 months |
| Minutes awake | Mean and standard deviation of minutes awake measures by activity and sleep tracker. | 36 months |
| Bed time Mean and standard deviation of bed time measures by activity and sleep tracker device. | 36 months |
| Number time awake Mean and standard deviation of number time awake measures by activity and sleep | 36 months |
| Background |
| Bier E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat Rev Genet. 2005 Jan;6(1):9-23. doi: 10.1038/nrg1503. |
| 29795158 | Background | Douglas AE. The Drosophila model for microbiome research. Lab Anim (NY). 2018 Jun;47(6):157-164. doi: 10.1038/s41684-018-0065-0. Epub 2018 May 23. |
| 38118419 | Background | Quesada-Vazquez S, Castells-Nobau A, Latorre J, Oliveras-Canellas N, Puig-Parnau I, Tejera N, Tobajas Y, Baudin J, Hildebrand F, Beraza N, Burcelin R, Martinez-Gili L, Chilloux J, Dumas ME, Federici M, Hoyles L, Caimari A, Del Bas JM, Escote X, Fernandez-Real JM, Mayneris-Perxachs J. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity. Cell Rep Med. 2023 Dec 19;4(12):101341. doi: 10.1016/j.xcrm.2023.101341. |
| 34777716 | Background | Mayneris-Perxachs J, Moreno-Navarrete JM, Ballanti M, Monteleone G, Alessandro Paoluzi O, Mingrone G, Lefebvre P, Staels B, Federici M, Puig J, Garre J, Ramos R, Fernandez-Real JM. Lipidomics and metabolomics signatures of SARS-CoV-2 mediators/receptors in peripheral leukocytes, jejunum and colon. Comput Struct Biotechnol J. 2021;19:6080-6089. doi: 10.1016/j.csbj.2021.11.007. Epub 2021 Nov 8. |
| 32665548 | Background | Lin H, Peddada SD. Analysis of compositions of microbiomes with bias correction. Nat Commun. 2020 Jul 14;11(1):3514. doi: 10.1038/s41467-020-17041-7. |
| 29273717 | Background | Albanese D, Donati C. Strain profiling and epidemiology of bacterial species from metagenomic sequencing. Nat Commun. 2017 Dec 22;8(1):2260. doi: 10.1038/s41467-017-02209-5. |
| 31441644 | Background | Zhao S, Li H, Han W, Chan W, Li L. Metabolomic Coverage of Chemical-Group-Submetabolome Analysis: Group Classification and Four-Channel Chemical Isotope Labeling LC-MS. Anal Chem. 2019 Sep 17;91(18):12108-12115. doi: 10.1021/acs.analchem.9b03431. Epub 2019 Sep 5. |
| 33027674 | Background | Arnoriaga-Rodriguez M, Mayneris-Perxachs J, Burokas A, Contreras-Rodriguez O, Blasco G, Coll C, Biarnes C, Miranda-Olivos R, Latorre J, Moreno-Navarrete JM, Castells-Nobau A, Sabater M, Palomo-Buitrago ME, Puig J, Pedraza S, Gich J, Perez-Brocal V, Ricart W, Moya A, Fernandez-Real X, Ramio-Torrenta L, Pamplona R, Sol J, Jove M, Portero-Otin M, Maldonado R, Fernandez-Real JM. Obesity Impairs Short-Term and Working Memory through Gut Microbial Metabolism of Aromatic Amino Acids. Cell Metab. 2020 Oct 6;32(4):548-560.e7. doi: 10.1016/j.cmet.2020.09.002. |
| 35176247 | Background | Mayneris-Perxachs J, Castells-Nobau A, Arnoriaga-Rodriguez M, Garre-Olmo J, Puig J, Ramos R, Martinez-Hernandez F, Burokas A, Coll C, Moreno-Navarrete JM, Zapata-Tona C, Pedraza S, Perez-Brocal V, Ramio-Torrenta L, Ricart W, Moya A, Martinez-Garcia M, Maldonado R, Fernandez-Real JM. Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans. Cell Host Microbe. 2022 Mar 9;30(3):340-356.e8. doi: 10.1016/j.chom.2022.01.013. Epub 2022 Feb 16. |
| 35508109 | Background | Mayneris-Perxachs J, Castells-Nobau A, Arnoriaga-Rodriguez M, Martin M, de la Vega-Correa L, Zapata C, Burokas A, Blasco G, Coll C, Escrichs A, Biarnes C, Moreno-Navarrete JM, Puig J, Garre-Olmo J, Ramos R, Pedraza S, Brugada R, Vilanova JC, Serena J, Gich J, Ramio-Torrenta L, Perez-Brocal V, Moya A, Pamplona R, Sol J, Jove M, Ricart W, Portero-Otin M, Deco G, Maldonado R, Fernandez-Real JM. Microbiota alterations in proline metabolism impact depression. Cell Metab. 2022 May 3;34(5):681-701.e10. doi: 10.1016/j.cmet.2022.04.001. |
| 37566655 | Background | Oliveras-Canellas N, Castells-Nobau A, de la Vega-Correa L, Latorre-Luque J, Motger-Alberti A, Arnoriaga-Rodriguez M, Garre-Olmo J, Zapata-Tona C, Coll-Martinez C, Ramio-Torrenta L, Moreno-Navarrete JM, Puig J, Villarroya F, Ramos R, Casado-Anguera V, Martin-Garcia E, Maldonado R, Mayneris-Perxachs J, Fernandez-Real JM. Adipose tissue coregulates cognitive function. Sci Adv. 2023 Aug 11;9(32):eadg4017. doi: 10.1126/sciadv.adg4017. Epub 2023 Aug 11. |
| 27100200 | Background | Xia D, Kelleher RJ 3rd, Shen J. Loss of Abeta43 Production Caused by Presenilin-1 Mutations in the Knockin Mouse Brain. Neuron. 2016 Apr 20;90(2):417-22. doi: 10.1016/j.neuron.2016.03.009. |
| Background | Wechsler, D. WAIS IV: Escala de Inteligencia de Wechsler para Adultos-IV. Madrid: TEA. 2012 |
| 34330904 | Background | Guo DH, Yamamoto M, Hernandez CM, Khodadadi H, Baban B, Stranahan AM. Beige adipocytes mediate the neuroprotective and anti-inflammatory effects of subcutaneous fat in obese mice. Nat Commun. 2021 Jul 30;12(1):4623. doi: 10.1038/s41467-021-24540-8. |
| 31935195 | Background | Guo DH, Yamamoto M, Hernandez CM, Khodadadi H, Baban B, Stranahan AM. Visceral adipose NLRP3 impairs cognition in obesity via IL-1R1 on CX3CR1+ cells. J Clin Invest. 2020 Apr 1;130(4):1961-1976. doi: 10.1172/JCI126078. |
| 34755095 | Background | Sodhi K, Pratt R, Wang X, Lakhani HV, Pillai SS, Zehra M, Wang J, Grover L, Henderson B, Denvir J, Liu J, Pierre S, Nelson T, Shapiro JI. Role of adipocyte Na,K-ATPase oxidant amplification loop in cognitive decline and neurodegeneration. iScience. 2021 Oct 12;24(11):103262. doi: 10.1016/j.isci.2021.103262. eCollection 2021 Nov 19. |
| 30256726 | Background | Morrison SF, Nakamura K. Central Mechanisms for Thermoregulation. Annu Rev Physiol. 2019 Feb 10;81:285-308. doi: 10.1146/annurev-physiol-020518-114546. Epub 2018 Sep 26. |
| 34408322 | Background | Cardoso F, Klein Wolterink RGJ, Godinho-Silva C, Domingues RG, Ribeiro H, da Silva JA, Mahu I, Domingos AI, Veiga-Fernandes H. Neuro-mesenchymal units control ILC2 and obesity via a brain-adipose circuit. Nature. 2021 Sep;597(7876):410-414. doi: 10.1038/s41586-021-03830-7. Epub 2021 Aug 18. |
| 26406372 | Background | Zeng W, Pirzgalska RM, Pereira MM, Kubasova N, Barateiro A, Seixas E, Lu YH, Kozlova A, Voss H, Martins GG, Friedman JM, Domingos AI. Sympathetic neuro-adipose connections mediate leptin-driven lipolysis. Cell. 2015 Sep 24;163(1):84-94. doi: 10.1016/j.cell.2015.08.055. |
| 31194997 | Background | Farruggia MC, Small DM. Effects of adiposity and metabolic dysfunction on cognition: A review. Physiol Behav. 2019 Sep 1;208:112578. doi: 10.1016/j.physbeh.2019.112578. Epub 2019 Jun 11. |
| 33164939 | Background | Gardener H, Caunca M, Dong C, Cheung YK, Rundek T, Elkind MSV, Wright CB, Sacco RL. Obesity Measures in Relation to Cognition in the Northern Manhattan Study. J Alzheimers Dis. 2020;78(4):1653-1660. doi: 10.3233/JAD-201071. |
| 22450854 | Background | Dahl AK, Hassing LB, Fransson EI, Gatz M, Reynolds CA, Pedersen NL. Body mass index across midlife and cognitive change in late life. Int J Obes (Lond). 2013 Feb;37(2):296-302. doi: 10.1038/ijo.2012.37. Epub 2012 Mar 27. |
| 34464646 | Background | Tang X, Zhao W, Lu M, Zhang X, Zhang P, Xin Z, Sun R, Tian W, Cardoso MA, Yang J, Simo R, Zhou JB, Stehouwer CDA. Relationship between Central Obesity and the incidence of Cognitive Impairment and Dementia from Cohort Studies Involving 5,060,687 Participants. Neurosci Biobehav Rev. 2021 Nov;130:301-313. doi: 10.1016/j.neubiorev.2021.08.028. Epub 2021 Aug 28. |
| 32479774 | Background | Qu Y, Hu HY, Ou YN, Shen XN, Xu W, Wang ZT, Dong Q, Tan L, Yu JT. Association of body mass index with risk of cognitive impairment and dementia: A systematic review and meta-analysis of prospective studies. Neurosci Biobehav Rev. 2020 Aug;115:189-198. doi: 10.1016/j.neubiorev.2020.05.012. Epub 2020 May 30. |
| 35760867 | Background | Endle H, Horta G, Stutz B, Muthuraman M, Tegeder I, Schreiber Y, Snodgrass IF, Gurke R, Liu ZW, Sestan-Pesa M, Radyushkin K, Streu N, Fan W, Baumgart J, Li Y, Kloss F, Groppa S, Opel N, Dannlowski U, Grabe HJ, Zipp F, Racz B, Horvath TL, Nitsch R, Vogt J. AgRP neurons control feeding behaviour at cortical synapses via peripherally derived lysophospholipids. Nat Metab. 2022 Jun;4(6):683-692. doi: 10.1038/s42255-022-00589-7. Epub 2022 Jun 27. |
| 29872139 | Background | Suarez AN, Hsu TM, Liu CM, Noble EE, Cortella AM, Nakamoto EM, Hahn JD, de Lartigue G, Kanoski SE. Gut vagal sensory signaling regulates hippocampus function through multi-order pathways. Nat Commun. 2018 Jun 5;9(1):2181. doi: 10.1038/s41467-018-04639-1. |
| 33473210 | Background | Minhas PS, Latif-Hernandez A, McReynolds MR, Durairaj AS, Wang Q, Rubin A, Joshi AU, He JQ, Gauba E, Liu L, Wang C, Linde M, Sugiura Y, Moon PK, Majeti R, Suematsu M, Mochly-Rosen D, Weissman IL, Longo FM, Rabinowitz JD, Andreasson KI. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature. 2021 Feb;590(7844):122-128. doi: 10.1038/s41586-020-03160-0. Epub 2021 Jan 20. |
| 30504920 | Background | Coin-Araguez L, Pavon FJ, Contreras A, Gentile AM, Lhamyani S, De Diego-Otero Y, Casado Y, Oliva Olivera W, Olveira G, Tinahones FJ, Perez Costillas L, El Bekay R. Inflammatory gene expression in adipose tissue according to diagnosis of anxiety and mood disorders in obese and non-obese subjects. Sci Rep. 2018 Nov 30;8(1):17518. doi: 10.1038/s41598-018-35759-9. |
| 25520251 | Background | Das SK, Ma L, Sharma NK. Adipose tissue gene expression and metabolic health of obese adults. Int J Obes (Lond). 2015 May;39(5):869-73. doi: 10.1038/ijo.2014.210. Epub 2014 Dec 18. |
| 16731815 | Background | Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006 Jun;55(6):1537-45. doi: 10.2337/db06-0263. |
| 31085992 | Background | Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, Beguinot F, Miele C. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019 May 13;20(9):2358. doi: 10.3390/ijms20092358. |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |